Clinical trials
Phase 3 programme (not yet enrolling)
Phase 3 programme of registration trials to confirm efficacy and safety in treating peanut allergy in patients aged 1 year through to adults.
Subscribe to our email updates for information about our upcoming clinical trials and notification when we begin recruitment.Camallergy’s treatments are investigational and not yet approved by regulatory agencies.
Early phase clinical trials
The phase 3 programme builds on the unprecedented results generated in our early phase clinical trials.
STOP2 showed strong, clinically relevant results in children, published in The Lancet. 84 and 91% of the two study groups were able to tolerate peanuts after oral immunotherapy, with further increasing levels of tolerance over time. There was 0% improvement in the control group.
Phase 2 study of 99 children aged 7 to 16 years, demonstrating safety and efficacy of oral immunotherapy to treat peanut allergy, subject to confirmation in phase 3
Phase 2 trial patients desensitized
STOP1
A proof-of-concept study of 22 children aged 4 to 17 years in the UK showed good tolerance of peanut OIT.